US4045547A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fabrication of soft contact lens and composition therefor
Assignee: AO Inc 14 MECHANIC ST A CORP OF
•
Filing: 1975-12-17
•
Granted: 1977-08-30
•
Expires: 1995-12-17
Abstract
Abstract A contact lens composition, having improved dimensional stability, suitable for use in the preparation of a corrective hydrated lens or an eye bandage, comprises polymerized random graft copolymers containing (in the dry state) from 67.2% to 79.3% HEMA; from 14.25% to 35% PVP; from 0.1% to 4.04% EDMA; from 0.1% to 2.5% MA; from 0.1% to 5.0% water; from 0 to 4 ppm HQ inhibitor; and from 50 to 250 ppm MEHQ inhibitor. The contact lens composition contains from 45% to 65% water after hydration. An improved method for shaping, polymerizing, and cutting and hydrating the contact lens composition is provided. The polymerization is conducted using only a low temperature initiator, by de-gassing prior to polymerization to remove substantially all oxygen, and by conducting the initial polymerization reaction at from 23 DEG C to 30 DEG C for 16 to 30 hours, during which the heat of the reaction is continuously absorbed to control the reaction exotherm. A closed, rod-shaped casting mold, lined with a polyester film material, is used and the polymeric rod obtained may be cut, machined and polished to obtain the contact lens composition. Thereafter, hydration is conducted in a buffered, 0.85% to 0.9% saline solution, at a pH of 7.0 to 7.1.
Inventors
- 👤 Albert R. Le Boeuf
- 👤 William R. Grovesteen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 08:09
CPC Classifications
A; A61; A61L; A61L15/00; A61L15/07; A61L15/12; A61L15/125; A61L15/16; A61L15/42; A61L15/44; B; B29; B29D; B29D11/00; B29D11/00009; B29D11/00038; B29D11/00067; B29D11/00125; B29D11/00134; C; C08; C08F; C08F271/00; C08F271/02; G; G02; G02B; G02B1/00; G02B1/04; G02B1/041; G02B1/043; A61L2300/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
198 words
A shaped eye bandage for medicament delivery which can be cut and shaped in the dry form and thereafter hydrated in a buffered saline solution to form a bandage having from about 45% to 65% water after hydration, said bandage in dry form consisting essentially of polymerized random graft copolymers containing from about 67.2% to about 79.3% HEMA; from about 14.25% to about 35% PVP; from about 0.1% to about 4.04% EDMA; from about 0.1% to about 2.5% MA; from about 0.1% to about 5.0% water; from about 0 to about 4 ppm, based on the weight of HEMA monomer, of HQ inhibitor; and from about 50 to 250 ppm, based on the weight of HEMA monomer, of MEHQ inhibitor; said composition having been polymerized in a three-stage polymerization process comprising: A. a first stage, using only a low temperature polymerization initiator, with substantially all the oxygen having been removed from the polymerization mix prior to and during the polymerization reaction; the initial polymerization reaction being conducted at from 23° C. to about 30° C., for from about 16 to about 36 hours, with the heat of the reaction continuously absorbed to control the reaction exotherm; followed by
Claim 2
Dependent Claim
198 words
A shaped eye bandage for medicament delivery which can be cut and shaped in the dry form and thereafter hydrated in a buffered saline solution to form a bandage having from about 45% to 65% water after hydration, said bandage in dry form consisting essentially of polymerized random graft copolymers containing from about 67.2% to about 79.3% HEMA; from about 14.25% to about 35% PVP; from about 0.1% to about 4.04% EDMA; from about 0.1% to about 2.5% MA; from about 0.1% to about 5.0% water; from about 0 to about 4 ppm, based on the weight of HEMA monomer, of HQ inhibitor; and from about 50 to 250 ppm, based on the weight of HEMA monomer, of MEHQ inhibitor; said composition having been polymerized in a three-stage polymerization process comprising: A. a first stage, using only a low temperature polymerization initiator, with substantially all the oxygen having been removed from the polymerization mix prior to and during the polymerization reaction; the initial polymerization reaction being conducted at from 23° C. to about 30° C., for from about 16 to about 36 hours, with the heat of the reaction continuously absorbed to control the reaction exotherm; followed by
Claim 3
Dependent Claim
45 words
B. A second stage, wherein the product of (A) is heated to a temperature of from about 40° C. to about 80° C. in the absence of any additional polymerization initiator, without control of the reaction exotherm, for from 2 to 6 hours; followed by
Claim 4
Dependent Claim
45 words
B. A second stage, wherein the product of (A) is heated to a temperature of from about 40° C. to about 80° C. in the absence of any additional polymerization initiator, without control of the reaction exotherm, for from 2 to 6 hours; followed by
Claim 5
Dependent Claim
47 words
C. A third stage polymerization, wherein the product of (B) is heated to a temperature of from about 105° C. to about 125° C., in the absence of any additional polymerization initiator, for from 24 to 36 hours; said bandage containing an opthalmologically acceptable medicament incorporated therein.
Claim 6
Dependent Claim
47 words
C. A third stage polymerization, wherein the product of (B) is heated to a temperature of from about 105° C. to about 125° C., in the absence of any additional polymerization initiator, for from 24 to 36 hours; said bandage containing an opthalmologically acceptable medicament incorporated therein.
Claim 7
Dependent Claim
134 words
A shaped eye bandage according to claim 1 wherein about 75.7% HEMA, about 19.4% PVP, about 0.54% EDMA, about 1.2% MA. about 3.0% water; from 0 to 4 ppm, based on the weight of the HEMA monomer, of HQ inhibitor, and from about 100 to 200 ppm, based on the weight of HEMA monomer, of MEHQ inhibitor are present in the substantially dry form of the contact lens composition, said dry form of the contact lens composition being cut and shaped and thereafter hydrated to contain from about 45% to about 65% water, said hydration being conducted in a 0.85% to 0.9% saline solution in combination with a fountain solution of an opthalmologically acceptable medicament, dissoolved in saline solution, said saline solution being buffered to maintain a pH of from about 7.0 to 7.1.
Claim 8
Dependent Claim
21 words
A shaped eye bandage according to claim 1 containing an opthalmologically acceptable medicament incorporated in the dry form of the bandage.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-08-29 | 1981-02-28 | 1981-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-08-29 | 1985-02-28 | 1985-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-08-29 | 1989-02-28 | 1989-08-30 | $7700.00 | Window Closed / Lapsed |